COX-2 inhibitors and cardiovascular risk: We defend our data and suggest caution

Cleveland Clinic Journal of Medicine

Volumn 68, Issue 11, 2001, Pages 963-964

  Mukherjee, Debabrata ^a   Nissen, Steven E ^b   Topol, Eric J ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL STUDY; CONTROLLED STUDY; DRUG SAFETY; HUMAN; HYPOTHESIS; METHODOLOGY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

EID: 0035189633     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.68.11.963     Document Type: Article

References (7)

1. Risk of cardiovascular events associated with selective COX-2 inhibitors
2. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits
3. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries
4. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo
5. Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs
6. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers
7. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study. A randomized controlled trial